Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + chidamide + docetaxel in PD-1 progressed advanced nonsquamous NSCLC
ChiCTR2400084939Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, tucidinostat and docetaxel in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Overall response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
adebrelimabtucidinostatdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400084939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084939.